In contrast, the 3,4-DHPEA-EA(P) treatment prevents the muscle degeneration process, suggesting the potential use of this molecule in high oxidative stress conditions (i.e., physical exercise, sarcopenia and aging) or during atrophy or to regulate the expression of transcription factors such as MyoD and MiRNA dependent on it. The gene discussed is MYOD1; the disease is sarcopenia.